The Department of Defense's Defense Health Agency awarded a $5,986,147 Project Grant to SPR Therapeutics, Inc. (doing business as SPR Therapeutics LLC) under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on July 1, 2024, will fund the development of a non-opioid peripheral nerve stimulation (PNS) system and lead designed specifically for use by U.S. service members to treat disabling pain. This innovative medical device aims to provide an alternative to opioid-based pain management solutions, potentially reducing reliance on opioids on the battlefield. The project will run through June 30, 2028, contributing to the program's goal of transforming military healthcare through impactful biomedical research.
Generated 1/14/25, 6:02 AM